More that 3 billions doses of China's CoronaVac and Sinopharm vaccines have been administered across the globe, playing an especially important role in Latin America and South East Asia, as well as China. These vaccines use inactivated virus particles to expose the immune system to Sars-CoV-2, but they do not appear to generate the same levels of neutralising antibodies as other vaccine platforms such as those based on mRNA. Now studies are suggesting that this protection may be waning more quickly than with other vaccines, which has sparked a conundrum - in many countries the only vaccines available are CoronaVac or Sinopharm. In this episode of Coronapod we ask how researchers are trying to get a handle on what is going on and how they might adapt to counteract waning immunity from these crucial vaccines.News: China’s COVID vaccines have been crucial — now immunity is waningSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.